Dr. Diwan also described the high efficacy of EKCCide?„? in a rabbit model, which caused complete clinical resolution of adenoviral kerato-conjunctivitis in as little as 2.5 days. The Company is not aware of any other drug candidate that had shown clinical improvement in this disease in any earlier animal studies.

Dr. Diwan also described the Social Responsibility programs of the Company, which include drug development against Dengue viruses, Rabies virus, as well as Biodefense programs that include broad-spectrum drug development against hemorrhagic viruses including Ebola/Marburg, and the ADIF?„? Accurate Drug In Field technology against novel and emerging viruses.

The Company has continued its development of FluCide, HIVCide, and the ocular nanoviricide eye drops, which are programs of very high commercial interest, said Dr. Eugene Seymour, MD, MPH, commenting further that, We continue to invest minimal amounts of Company funds in the Social Responsibility and Biodefense projects, and we will require public funding for the same.

nanoviricides/